Clinical and Radiological Features of Ischemic Stroke in Patients with Antiphospholipid Antibody Syndrome: A Case Series Report
Main Article Content
Abstract
Objective: To describe the clinical, radiological, and laboratory characteristics of ischemic strokes associated with antiphospholipid antibody (APS) syndrome.
Background
Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) that contribute to a prothrombotic state, leading to both venous and arterial thrombosis. Clinically, APS is associated with significant morbidity due to recurrent thrombotic events, thrombocytopenia, and recurrent pregnancy loss, with cerebral ischemia being the most prevalent arterial manifestation. The mechanisms by which aPL induces thrombotic events are complex and multifactorial, involving endothelial cell activation, platelet aggregation, and interference with coagulation pathways. These pathogenic effects, exerted by aPL, substantiate the role of APS in cerebrovascular events such as ischemic stroke.
While APS is recognized as a significant contributor to stroke, particularly in young patients, the clinical and radiological characteristics of APS-associated stroke remain underexplored. Currently, there is no specific clinical or imaging profile to distinctly identify APS-related ischemic strokes. Given this gap, there is an imperative to characterize the clinical presentations and radiographic findings in APS patients to aid early identification and tailored management. This case series aims to elucidate the clinical, laboratory, and radiological features of APS in young stroke patients, emphasizing the importance of aPL testing in this population.
Methods
This retrospective case series analyzed the clinical, laboratory, and radiological data of patients under 45 years of age who were diagnosed with antiphospholipid antibody syndrome (APS) as the etiology of ischemic stroke at two major government hospitals in the United Arab Emirates. Each patient underwent comprehensive testing for antiphospholipid antibodies (aPL) upon admission, followed by confirmatory testing during a follow-up visit within 3–5 months. Clinical variables, aPL profile, stroke presentation, and imaging findings were systematically reviewed. Patients received anticoagulation therapy following diagnosis.
Results
Among the ten patients diagnosed with APS-related ischemic stroke, the median age was 34 years (range 26–52), with a male-to-female ratio of 4:1. Secondary APS was identified in one patient with systemic lupus erythematosus, while the remaining nine cases were primary APS. Lupus anticoagulant was detected in four patients, anticardiolipin antibodies in five, and β2-glycoprotein antibodies in two. Aphasia was the predominant clinical presentation (observed in 8 of 10 cases), often accompanied by hemiparesis. Stroke localization predominantly involved the M2 segment of the middle cerebral artery, resulting in perisylvian infarcts, particularly affecting the left hemisphere. One patient developed a concurrent pulmonary embolism during hospitalization. Laboratory findings showed mild thrombocytopenia in three patients, with elevated activated partial thromboplastin time (aPTT) observed in six patients.
Conclusion
Ischemic strokes associated with antiphospholipid antibody syndrome (APS) predominantly localize to the perisylvian region within the M2/M3 branches of the middle cerebral artery, exhibiting clinical and radiological features that closely resemble those of cardioembolic strokes. Elevated activated partial thromboplastin time (aPTT) and thrombocytopenia were observed as potentially sensitive laboratory markers indicative of APS. Given the overlap in presentation with other stroke etiologies, it is recommended that antiphospholipid antibody testing be integrated into the diagnostic workup for all young patients exhibiting suggestive clinical and radiological findings, alongside a comprehensive cardiac evaluation, irrespective of traditional vascular risk factors. Early identification and management of APS in these patients may reduce the risk of recurrent thrombotic events and improve clinical outcomes.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Gaspar, Paulo, Hannah Cohen, and David A. Isenberg. "The Assessment of Patients with the Antiphospholipid Antibody Syndrome: Where Are We Now?" Rheumatology 59, no. 7 (2020): 1489-1494. https://doi.org/10.1093/rheumatology/keaa172.
3. Xourgia, Eleni, and Maria G. Tektonidou. "An Update on Antiphospholipid Syndrome." Current Rheumatology Reports 23, no. 12 (2022): 84. https://doi.org/10.1007/s11926-021-01051-5.
4. Cervera, Ricard, Maria Chiara Boffa, Munther A. Khamashta, and Graham R. Hughes. "The Euro-Phospholipid Project: Epidemiology of the Antiphospholipid Syndrome in Europe." Lupus 18, no. 10 (2009): 889-893.
https://doi.org/10.1177/0961203309106832.
5. Barbhaiya, Medha, Sylvie Zuily, Rodney Naden, Allan Hendry, Fanny Manneville, Maria C. Amigo, Zahir Amoura, et al. "2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria." Annals of the Rheumatic Diseases 82, no. 10 (2023): 1258-1270. https://doi.org/10.1136/ard-2023-224609.
6. Tektonidou, Maria G., Laura Andreoli, Zahir Amoura, Ricard Cervera, Nathalie Costedoat-Chalumeau, Munther A. Khamashta, Marc J. Cuadrado, et al. "EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults." Annals of the Rheumatic Diseases 78, no. 10 (2019): 1296-1304.
https://doi.org/10.1136/annrheumdis-2019-215213.
7. Jerez-Lienas, Alicia, Amelie Mathian, Julien Aboab, Isabelle Crassard, Marc Hie, Florence Cohen-Aubart, Jérôme Haroche, et al. "Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature." Brain Sciences 11, no. 12 (2021): 1641. https://doi.org/10.3390/brainsci11121641.
8. Fan, Yangyi, Yicheng Xu, Sifan Zhang, Xiaodong Song, Zunjing Liu, Wenjun Tu, and Chun Li. "Stroke and Risk Factors in Antiphospholipid Syndrome." Journal of Personalized Medicine 14, no. 1 (2024): 24.
https://doi.org/10.3390/jpm14010024.
9. Knight, Jason S., and Yogesh Kanthi. "Mechanisms of Immunothrombosis and Vasculopathy in Antiphospholipid Syndrome." Seminars in Immunopathology 44, no. 3 (2022): 347-362. https://doi.org/10.1007/s00281-022-00916-w.
10. Cohen, Hannah, David J. Werring, Amit Chandratheva, Paras Mittal, Koen M. J. Devreese, David A. Isenberg, and the ISTH SSC Lupus Anticoagulant/Antiphospholipid Antibodies Subcommittee Study Group. "Survey on Antiphospholipid Syndrome Diagnosis and Antithrombotic Treatment in Patients with Ischemic Stroke, Other Brain Ischemic Injury, or Arterial Thromboembolism in Other Sites: Communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies." Journal of Thrombosis and Haemostasis 21, no. 10 (2023): 2963-2976. https://doi.org/10.1016/j.jtha.2023.06.020.
11. Leal Rato, Margarida, Mariana Bandeira, Vanessa C. Romão, and Diana Aguiar de Sousa. "Neurologic Manifestations of the Antiphospholipid Syndrome - an Update." Current Neurology and Neuroscience Reports 21, no. 8 (2021): 41. https://doi.org/10.1007/s11910-021-01124-z.
12. Ricarte, Isabel F., Cecilia Marino, Maria Rosa Maccarrone, Roberto Testa, Giacomo Lana-Peixoto, Graciela S. Alarcon, and Gustavo C. Alonso. "Neurologic Manifestations of Antiphospholipid Syndrome." Lupus 27, no. 9 (2018): 1404–1414. https://doi.org/10.1177/096120331877611.
13. Liu, Min, Gaoming Li, Xun Song, Yangyi Fan, and Chun Li. "Prevalence, Risk Factors, and Prognosis of Central Nervous System Manifestations in Antiphospholipid Syndrome." Scientific Reports 13, no. 1 (2023): 8915.
https://doi.org/10.1038/s41598-023-35955-2.
14. Engelter, Stefan T., Matthias Gostynski, Steffen Papa, Mirjam Frei, Christoph Born, Vladeta Ajdacic-Gross, Hans Peter Schroth, et al. "Epidemiology of Aphasia Attributable to First Ischemic Stroke: Incidence, Severity, Fluency, Etiology, and Thrombolysis." Stroke 37, no. 5 (2006): 1379-1384. https://doi.org/10.1161/01.STR.0000221815.64093.8c.
15. Pierik, Ramon, Ale Algra, Ewoud van Dijk, Michiel E. Erasmus, Isabella C. van Gelder, Peter J. Koudstaal, Gert-Jan R. Luijckx, et al. "Distribution of Cardioembolic Stroke: A Cohort Study." Cerebrovascular Diseases 49, no. 1 (2020): 97-104. https://doi.org/10.1159/000505616.
16. Graf, J. "Central Nervous System Manifestations of Antiphospholipid Syndrome." Rheumatic Diseases Clinics of North America, vol. 43, no. 4, 2017, pp. 547-560. https://doi.org/10.1016/j.rdc.2017.06.004.
17. Charitha, K., et al. "Precision Imaging in Neurodegeneration: The Superiority of Diffusion Tensor Imaging Over Conventional MRI in Differentiating Parkinson's Disease From Atypical Parkinsonian Syndromes." Cureus, vol. 16, no. 9, 2024, e68933. https://doi.org/10.7759/cureus.68933.
18. Zhao, J., et al. "Dancing with Disorder: Chorea - an Unusual and Neglected Manifestation of Antiphospholipid Syndrome." Lupus Science & Medicine, vol. 11, no. 2, 2024. https://doi.org/10.1136/lupus-2024-001332.